WO2004039996A1 - Mthod for producing recombinant human interferon alpha 2b polypeptide in pichia pastoris - Google Patents
Mthod for producing recombinant human interferon alpha 2b polypeptide in pichia pastoris Download PDFInfo
- Publication number
- WO2004039996A1 WO2004039996A1 PCT/IN2002/000216 IN0200216W WO2004039996A1 WO 2004039996 A1 WO2004039996 A1 WO 2004039996A1 IN 0200216 W IN0200216 W IN 0200216W WO 2004039996 A1 WO2004039996 A1 WO 2004039996A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- protein
- ifn alpha
- alpha
- gene
- ifn
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/555—Interferons [IFN]
- C07K14/56—IFN-alpha
Definitions
- the present invention relates to an immunomodulatory protein useful as antiviral and antitumor agent.
- the present invention relates to a novel gene encoding human IFN alpha 2b protein
- the present invention also relates to novel polynucleotides used to isolate the novel gene; inserting the said gene in a suitable host; producing the culture of recombinant strain and stimulating expression of the heterologous polypeptide and its secretion.
- the invention also provides a method for high density fermentation process for production of interferon alfa 2b along with a suitable protein purification process for the same.
- this invention relates to the preparation of human leukocyte IFN alpha 2b protein in high yields using a corresponding novel gene inserted in a recombinant Pichia pastor is strain.
- Pestka S. European Patent Application 81105067.3 (1982); Pestka S., Methods in Enzymology, 119: 3-14, 14-23 (1986 ;Lawn R. M., et al, Proc. Natl. Acad. Sci. USA, 78, 5435-5439, (1981); Dworkin-Rastl E., et al, J. Interferon Research, 2, 575-585, (1982)].
- IFN alpha subtypes There are four main subtypes of interferon's, among which alpha or leukocyte interferon's are more common. These are also called as Type I interferon and are distinctly smaller in size, stable upto pH 2 and are glycoproteins.
- IFN alpha 2a The major subtype gene of IFN alpha 2, is further subdivided into three classes which have been identified as (alpha 2a, alpha 2b, and alpha 2c). Generally in humans IFN alpha 2b is expressed more frequently.
- IFN subtypes includes nearly 20 genes, namely IFN-alpha la, -alpha lb, -alpha 4a, -alpha 4b, -alpha 5, -alpha 6 etc [Streuli M., et al, Science, 209: 1343-7 (1980); Emanuel S.L., and Pestka, S., J. Biol.
- interferon infections include, but are not limited to: herpes simplex keratitis, acute hemorrhagic conjunctivitis, variacella zoster, cytomegalovirus infection, respiratory infections; including its uses in the treatment of genital warts [Bones R., Atkinson G., WO 98/23285, (1998).], hepatitis B [Ge ert D., Salom C, et al, J Interferon Res., 13 (3), 227-231, (1993)] and psoriasis [Meritet J, et al, WO 01/42301, (2001)].
- Other infections wherein treatment of interferon has been found to be useful include bacterial infections [ubin D., US 4,762,705, (1988); Cummins J., et al, US 5,830,456, (1988).
- Type I interferon's are reported to be useful in treating cancers [Tanner D., et al, US 5,028,422, (1991); Tanner D., et al, US 5,256,410, (1993); Del B., US 5,024,833, (1991); Wadler S., et al, US 5,444,064, (1995); Wadler S., et al, US 5,814,640, (1995); Peets E.A., et al, US 5,002,764, (1991)], such as leukemias, basal carcinomas, squamous cell carcinomas, breast cancer, gastrointestinal malignancies, Kaposi's sarcoma, CML, B-cell and T-cell lymphomas, melanomas, renal cell carcinoma, ovarian, bronchogenic, bladder, and acute leukemias, malignant glio a and fibrosarcoma.
- interferons are also used for actinic keratoses [Wong V.G., et al, US 5,632,984 (1997)].
- macular degeneration [Osther K. B., WO 98/06431 A2, (1998)]
- autoimmune disorders [Rusch L., WO 01/22970, (2001)]
- diabetes Bonnem E., US 4,846,782 (1989)].
- a method using IFN to selectively induce a programmed cell death (apoptosis) in cancerous cells is also provided [Carswell R.E., et aL, EP 01/31789 (1985)].
- interferon As interferon have a species-specific activity, for its clinical use in humans; the protein should be obtained from genetic material directly related to the human interferon [Lin L., et al, J. Gen. Virol., 39:125-130, (1978).].
- Various protein formulations of IFN are in clinical use [Sen G., et al, J. Virol., 50(2):445-450, (1984); Jones G., et al, Cancer, 57:1709-1715, (1986); Klingemann H.G., et.
- IFN alpha subtypes include leukocytes [Cantell K., et al, Methods in Enzymol. , Academic Press, N.Y., 78:29-38, (1981); Khavkin T., et al, J. Leukocyte Biology, Annual Meeting Abstracts, Suppl. 3, Abstr.
- rDNA technology has made it possible to obtain IFN with relative ease and safety.
- Appropriate cloning and expression vectors which have been used for r-IFN production include bacterial, fungal, yeast and mammalian cellular hosts [Pestka S, Human Cytokines,
- Yeast cell has features such as ease of genetic manipulation and rapid growth characteristics like prokaryotic organism and biological characteristics typical of eukaryotic cell. This includes the sub-cellular machinery to carry our post-translational modification, which is desired. Commonly used yeast's include Hansenula polymorpha, S. cerevisiae and Pichia pastoris etc. strains, which are easier to work with variety of foreign genes. To prepare recombinant proteins, methylotrophic yeasts are most attractive candidates as it has certain genes, which are highly regulated and expressed under induced or de-repressed conditions [Nagata S, et. al. Nature, 284:316-310, (1980)].
- the desired gene can either be isolated from a cDNA library of human leukocyte or obtained from genomic libraries that are commercially available.
- mRNA isolated from human leukocytes can be utilized to obtain gene of interest by the known methods in prior art [Desai M, et. al, J. Interferon Res, 12: S138, (1992) Cantell K, et al, Methods in Enzymol, Academic Press, N.Y, 78:29-38, (1981); Khavkin T, et al, J. Leukocyte Biology, Annual Meeting Abstracts, Suppl 3, Abstr. 137:36 (1992).;Wheelock E. F, J. Bact. 92, 1415-1421, (1966); Ellis S.B, et. al, Mol Cell. Biol, 9, 1316-1323, (1985);].
- inducers such as. viruses, natural or synthetic double-stranded RNA, intracellular microbes, microbial products and various other chemical agents.
- the methods are available to isolate mRNA having an abundance of messages coding for human IFN alpha [Chirgwin J.M, et al. Biochemistry, 18: 5294, (1979); Stewart W. E, The Interferon System, Springer, Berlin, (1979);Hiscott I, et aL, Nucl. Acids. Res, 12, 3727-3746 (1984).].
- the mRNA isolated can be used to prepare cDNA of the present invention according to the methods described in prior art [Rubinstein M, et al. Methods in Enzymology, Academic Press, N.Y, 78A, 69-75, (1981).].
- the cDNA can be converted into dsDNA using gene specific primers.
- dsDNA molecules can be cloned in suitable vectors and transformed into appropriate host such as E. coli or yeast
- a construct may include, an expression cassette comprising of a transcription promoter (T7, AOXl,Gal3) a gene encoding the polypeptide or protein of interest (e.g., dsDNA), and a transcription terminator (e.g., an AUG1 terminator, an AOX1 terminator, etc.).
- T7, AOXl,Gal3 a gene encoding the polypeptide or protein of interest
- a transcription terminator e.g., an AUG1 terminator, an AOX1 terminator, etc.
- the present invention aims to provide a method of producing novel recombinant DNA which encodes a polypeptide displaying immunological and biological activities of mature human interferon alpha 2b. Another objective of the present invention is to produce interferon alfa 2b by high density fermentation. Yet another objective of the present invention is to obtain IFN alpha 2b protein in a pure form. A further object of the present invention is to prepare a pharmaceutical composition comprising of the said recombinant human IFN alpha 2b protein or its pharmaceutically acceptable salt together with a pharmaceutically acceptable carrier or excipients. A still further objective of the present invention is to prepare a pharmaceutically acceptable formulation of recombinant human IFN alpha 2b protein or its pharmaceutically acceptable salt for their uses in various diseases as mentioned herein.
- the present invention describes a novel DNA encoding human IFN alpha 2b protein and its method of production and purification.
- the process also involves novel oligonucleotides used as primers while isolating the novel gene.
- the appropriate gene after isolation is inserted into plasmid, which is further propagated in bacteria and later in yeast to give transformants having gene encoding for recombinant human IFN alpha 2b protein.
- the preferred cells for production of proteins for commercial use are methylotropic yeast.
- high- density cell culture of recombinant yeast is prepared by maintaining appropriate fermentation parameters. Later recombinant yeast cells are induced to produce desired protein in high yields.
- the said protein is purified by a novel purification process.
- the said purified protein is found to have all physiological, immunological and biochemical characteristics similar to mature human interferon alpha 2b protein.
- FIG 1 shows the sequence (SEQ. ID. No. 1) of modified human interferon alpha 2b of the present invention.
- FIG.2(a) Shows a sequence (SEQ. ID NO. 2) of IFN alpha 2b gene obtained from NCBI GenBank database wherein 57 th nucleotide is 'A' and 195 th nucleotide is 'T' in IFN alpha 2b gene.
- FIG. 2(b) Shows the sequence (SEQ.ID.NO. 3) of human interferon alpha 2b of present invention which matches with the gene sequence deposited at the Gene Bank database (SEQ. ID. NO. 2) except at the 57 tt position wherein instead of 'A', in the present invention there is 'G' and at the 195 position wherein instead of 'T', in the present invention there is 'C.
- FIG. 3 Shows a restriction endonuclease digested and purified pPICZ alphaA DNA and
- IFN alpha 2b gene insert along with 1 kb ladder marker, on an agarose gel stained by ethidium bromide (fluorescent dye), wherein, from left to right.
- Lane 1 IFN alpha 2b insert (-498 bp)
- FIG. 4 Displays a recombinant pPICZ alphaA vector hav g IFN alpha 2b gene insert as shown by the mobility shift (Lane 4) on agarose gel wherein, from left to right. Lane l: 1 kb DNA ladder.
- Lane 2 ZBT alpha plasmid DNA
- FIG. 5 Discloses the characterization of ZBT-IF 2.2 clones by PCR analysis prior to cloning into Pichia pastor is, wherein, from left to right.
- Lane 1 Negative Control PCR product with gene specific primers where no amplification is observed
- Lane 2 PCR product from ZBT-IF 2.2 plasmid DNA with gene specific primers
- FIG. 6 PCR amplification of the IFN alpha 2b gene from the total genomic DNA isolated from Pichia pastoris clones (ZIF.2.2 series), wherein, from left to right: Lane 1 to 6: PCR product from Pichia pastoris ZIF clone 2.2/1,2,3,4,5,6,7 clones genomic DNA with vector specific primers Lane 7: 1 kb ladder marker.
- FIG. 7 shows SDS-PAGE of IFN alpha 2b polypeptide wherein, from left to right: Lane 1 : Low molecular weight marker.
- Lane 2 European reference standard of IFN alpha 2b
- Lane 3, 4 Show pure IFN alpha 2b protein of present invention.
- FIG. 8 shows Western blot of purified IFN alpha 2b protein produced by clone Pichia pastoris ZIF clone 2.2/14, wherein, from left to right:
- Lane 1& 2 IFN alpha 2b protein of present invention
- Lane 3 European Reference standard.
- Lane 4 Prestained Low molecular weight Markers ( BIO-RAD) FTG.9: shows Isoelectric focusing of purified IFN alpha 2b produced by clone Pichia pastoris ZIF clone 2.2/14 wherein, from left to right:
- Lane 1 Pure IFN alpha 2b protein of present invention Lane 2 pi Markers (pi range 2.5 to 6.5) Lane 3 European Reference standard
- FIG. 10 shows LCMS of pure IFN alpha 2b produced by clone Pichia pastoris ⁇ F clone 2.2/14.
- Novel DNA of the present invention encodes human interferon alpha 2b, specifically DNA comprising the base sequence as set forth in ⁇ Fig. 2b ⁇ (SEQ ID 3).
- SEQ ID 3 The complete physical map of type-I interferon gene cluster and its location in chromosomes is known [Diaz M. O, et. al, J.
- the novel DNA of the present invention was found to have > 99 % homology with corresponding part of some IFN subtypes deposited at NCBI GenBank database.
- the nearest matching known IFN alpha 2b sequence is described in FIG. 2a (SEQ ID 2).
- the novel DNA sequence of the present invention has a distinct nucleotide 'Guanine' at 57 th position, instead of 'Adenine' and 'Cytosine' at 195 th position instead of 'Thymine' in comparison with the homologous sequences of human IFN alpha 2b gene.
- another characteristic of this invention includes the protein encoded by said sequence has similarity to mature IFN alpha 2b protein in its primary structure.
- interferon alpha 2b protein may be in the form of acidic or basic salts, or may be in a neutral form. Individual amino acids may be modified by oxidation or reduction.
- the primary amino acid structure may be modified by forming covalent or aggregate conjugates with other chemical moieties, such as glycosyl groups, lipids, phosphate, acetyl, hydroxyacetyl, amido groups and the like, or by creating amino acid mutants.
- chemical moieties such as glycosyl groups, lipids, phosphate, acetyl, hydroxyacetyl, amido groups and the like, or by creating amino acid mutants.
- Interferon alpha 2b or “IFN alpha 2b” refers to protein having amino acid sequences which are similar to the native mammalian interferon alpha 2b, which are capable of initiating response from Type I interferon receptor.
- the mature full-length human IFN- 2b is usually a glycoprotein having a molecular weight of about 19.268 kilodaltons (kDa).
- Modified Interferon alpha 2b refers to a nucleotide sequence having eighteen additional nucleotides at the 5 ' end than the natural IFN alpha 2b .
- isolated or “purified”, as used in the context of this specification to define the purity of interferon protein, means that the protein is substantially free of other proteins of natural or endogenous origin and contains less than about 1% by mass of protein contaminants residual of production processes.
- Recombinant as used herein, means that a heterologous protein is derived from recombinant (e.g. microbial or mammalian) expression systems.
- Microbial refers to bacterial or fungal (e.g. yeast) expression systems.
- Recombinant microbial product defines a protein produced in a recombinant microbial expression system, which is essentially free of native endogenous substances.
- the purified m-RNA was used to prepare first strand of DNA by RT-PCR technique.
- the present process utilizes six sets of novel primers, which are specific for human IFN alpha.
- the nucleotide sequences of the first set of primers used to amplify the genes are shown in SEQ ID NOs.; 4 & 5; 6 & 7; of Table 2.
- the PCR products obtained with primers SEQ. ID NO. ; 4 & 5 and 6 & 7 were used for cloning of modified human IFN alpha 2b gene in cloning vector.
- Another set of primers (SEQ ID NOs.8 & 9 /10 &11), were used for subcloning of modified human IFN alpha 2b gene in suitable expression vector, which encodes for modified human IFN alpha 2b protein .
- the so obtained modified IFN alpha 2b clone was used further for cloning of mature human IFN alpha 2b using another set of primers (SEQ ID Nos. 12 & 13 or 12 & 14) to obtain a gene which encodes for human IFN alpha 2b protein.
- Suitable restriction endonuclease site such as EcoRI, Xhol site in the forward primer, while in reverse primer Xba I or Not I restriction sites may be incorporated in these oligonucleotides.
- oligonucleotide primers can be synthesized using the known techniques in the prior art [Broka C, et. al. Nucleic Acids Res, 8, 5461-5471 (1980); Beaucage, S. L, and Carothers, M. H, Tetrahedron Lett. 22, 1859-1862, (1981); Johnson B. A, et al, Biotechniques 8, 424-429, (1990)]. They can also be synthesized in automated oligonucleotide synthesizers for e.g., Oligo 1000 (Beckman, USA) using phosphoramidites and oligonucleotide synthesis kit. Alternatively, custom designed synthetic oligonucleotides may be purchased, for example, from Bangalore Genei (Bangalore, India).
- the vector used to clone gene of interest may include plasmids derived from various sources such as E. coli, for e.g. pBR322, pBR325, pUC12, pUC13, M13mpl8 etc.; Bacillus subtilis, for e.g. pUBHO, pTP5, pC194, etc.; yeast for e.g.
- bacteriophages such as lambda phage: and other vectors such as pAT-11, pXTl, pRc/CMV, pRc/RSV, pcDNAI/Neo and the like [Maeda S, et al, Proc. Natl. Acad. Sci. USA 77, 7010-7013 (1980); 78, 4648 (1981); Raymond C. K, et al, BioTechniques 26(1):134-141 (1999)].
- the preferred plasmid in the present invention is M13mpl8 and pPICZ alphaA.
- the amplified PCR products were cloned in M13mp 18 and propagated in E. coli JM109. A blue white screening was carried out to select the recombinant E. coli having the gene of present invention.
- the modified IFN alpha 2b was subcloned independently in pPICZ alphaA expression ⁇ 'ector. The inserted DNA were amplified, isolated and sequenced. This modified clone was subsequently used for isolation and cloning of the mature IFN alpha 2b gene in a suitable expression vector. The so obtained clone of human IFN alpha 2b was isolated and sequenced. The nucleotide sequence was compared with the known gene sequences deposited at the NCBI GenBank database.
- the expression vectors can either have genes acting as selective markers by imparting antibiotic resistance to the cells, such as G418 and other neomycin-type antibiotics (kanamycin resistance gene), or bleomycin/phleomycin-type antibiotics such as ZEOCIN (ble genes), as well as ampicilin resistance genes; or it may have gene for selective utilization of particular substrate for e.g. galactose, presence/absence of particular amino acid and the like.
- selectable marker should be able to provide resistance in transformed yeast as well as bacteria.
- promoter depends upon the host cell used for the transformation/ recombinant gene expression.
- suitable promoter can be used such as SV40 promoter, LTR promoter, CMV promoter, HSV-TK promoter and the like.
- the suitable promoter can be trp promoter, lac promoter, lambda PL promoter, lpp promoter, T7 promoter and the like.
- suitable promoters can be PHO5 promoter, PGK promoter, AOX1 and AOX2 promoter [Rodriguez L, et al. Yeast, 12:815 (1996); Said Y, et al, U.S. Pat.
- GAP promoter [Waterham H. R, et al, Gene 186:37 (1997); Rosenberg S, et. al, U.S. Pat. No. 5,089,398.], ADH promoter and the like. Suitable promoters can be identified by its function according to known methods. The promoters of methylotrophic yeast, involved in methanol metabolism are particularly strong, and these are generally used to control the heterologous expression of proteins [Hollenberg C. P, et. al, EP 0173 378 (1991); Viader S. J, EP 0952158, (1999); StromanD. W, et al, EP 0183 071 (1992); ].
- Escherichia species include strains such as Escherichia coli DH1 [Low B, PNAS, 60: 160 (1968)], JM103 [Messing J, et al, Nucl. Acids Res, 9:309 (1981)], JA221 [Clarke L, et al, J Mol.
- HB101 Bacillus subtilis Mil 14 [Yoshimura K, Gene, 24: 255 (1983)] and the like.
- suitable mammalian host cells includes, COS-7, monkey kidney cells [Gluzman Y, Cell 23:175, (1981) ], L cells, C127, 3T3, Chinese hamster ovary (CHO), Hela and BHK cell lines and the like.
- yeast cells which can be used include, for example, Saccharomyces cerevisiae AH22, AH22R " , NA87-11 A, DKD-5D or 20B- 12, Schizosaccharomyces pombe NCYC 1913, Hansenula, Candida, or Pichia etc. It is preferable to use yeast cells to obtain the protein of this invention. It is more preferable to use methylotrophic yeast such as Pichia pastoris KM71 for the reason cited above.
- an expression vector which comprises of a secretory signal sequence to drive secretion of expressed heterologous proteins.
- a typical secretory peptide consists of about 20 amino acids and it has a hydrophobic core of 6 to 15 amino acids followed by hydrophilic amino acid residues.
- Suitable secretory signal sequences can be preferably derived from Saccharomyces cerevisiae or Pichia pastoris species and are exemplified by invertase gene (SUC2), acid phosphatase gene (PHOl and PHO5), alkaline phosphatase gene, or alpha mating factor (MF.alpha.l), as well as a synthetic hybrid based on the PHOl sequence.
- the present invention has 85-89 amino acid long secretary signal, bearing kex2 and STE3 endopeptidase cleavage site as described by Brake et. al [Brake A. J, et al, PNAS, 81:4642-46 (1984).] and has yeast mating factor alpha as a preferred secretory signal.
- the method for transformation depends upon the host cells selected in accordance to standard techniques.
- the prior art describes methods to carry transformation for Escherichia species [Cohen S. N, et al, PNAS, 69:2110 (1972); Reid J. D, et. al. Gene, 17: 107 (1982)], Bacillus species [Chang S, et al. Molecular & General Genetics, 168:111 (1979)], yeast cells [Becker D. M, et. al. Methods in Enzymology, 194: 182-187 (1991); Hinnen A, et. al, Proc. Natl. Acad. Sci. USA, 75:1929 (1978)] and animal cells [Chang S, et al.
- Methylotrophic yeast cells are preferred [Sudbery P, Curr. Opin. Biotech, 7:517 (1996); .Gabain A, et. al, Biotechnol. Appl. Biochem, 33(3):173, (2001); Higgins D. R, and Cregg J.
- transformants or transfectants wherein the expression vector carries at least one copy of functional DNA can be isolated according to the aforementioned techniques.
- the culture of tranformants can be prepared as described below.
- Escherichia or Bacillus species can be suitably cultured in a liquid culture medium, wherein the culture medium contains appropriate carbon, nitrogen, and mineral sources, necessary for the growth.
- the carbon sources may include glucose, dextrin, soluble starch, sucrose, etc.
- the nitrogen sources may include organic or inorganic substances such as ammonium salts, nitrates, corn steep liquor, peptone, casein, meat extracts, bean-cakes, potato extracts, etc.
- the minerals may include calcium chloride, sodium dihydrogen phosphate, magnesium chloride, etc. It is further allowable to add yeast's, vitamins, growth-promoting factors, etc. It is suitable that the pH of culture medium is at about 5 to 8.
- the culture medium used may include available commercial preparations and standard media found in literature. It is preferable to keep the pH of the culture medium in between 3 to 6, kept at about 25 to 35 °C for about 24 to 72 hrs along with aeration and stirring if required.
- the culture medium used may include MEM medium, DMEM medium, RPMI 1640 medium, which may contain 5 to 20 % of fetal calf serum.
- the culture has pH of about 6 to 7 and is incubated at 30 to 40 °C for 15 to 60 hrs in 5-7% CO 2 , environment. If required medium exchange, aeration and stirring may be applied.
- methylotrophic yeast especially Pichia species is the preferred organism.
- the suitable transformants obtained described above were labeled as Pichia pastoris ZIF clone 2.2 series.
- the transformants obtained were verified for the presence of interferon alpha 2b gene.
- the transformants may have differences in expression levels of heterologous proteins, resulting due to factors such as the site of integration and copy number of the expression cassette and differences in promoter activity among individual isolates.
- Various screening methods to identify suitable transformants are available, which includes, for example, protein specific ELISA based assay or immunoblotting with IFN alpha 2b specific antibodies or specific HPLC assays.
- the recombinant clones of Pichia pastoris ZIF 2.2 series were screened for expression of the said proteins of this invention.
- the clone Pichia pastoris ZIF 2.2/14 producing the human IFN alpha 2b protein was selected and the expressed protein was characterized further for its biological and immunological equivalence with the mature native human IFN alpha 2b.
- the IFN alpha 2b protein expressed was confirmed on SDS-PAGE, (FIG. 7). Further the purified protein of this invention was compared with European Reference standard of IFN alpha 2b protein (CRS batch 2, catalogue no. I 0320301) by SDS-PAGE, IEF as a reference protein as described in FIG. 9.
- a preferred expression host in this invention is methylotrophic yeast, examples of which includes suitable strains of Pichia methanolica, Hansenula polymorpha, Pichia pastoris and the like, more preferably Pichia pastoris strain as described earlier.
- the preferred Pichia pastoris transformants should carry at least one copy of an expression cassette comprising an alcohol- inducible promoter, secretory signal sequence, a novel DNA encoding for IFN alpha 2b protein, a transcription termination signal and a selection marker.
- the unique fermentation process of this invention comprises of producing a high- density cell-culture of novel Pichia pastoris ZIF 2.2/14 clone and expression of heterologous protein under suitable conditions.
- the typical fermentation protocol of the present invention provides conditions for high- density cell-mass build-up.
- the protocol has some characteristics of fed batch process of fermentation.
- the rate of addition of feed supply is related with the growth rate of cells, rate at which carbon and nitrogen are assimilated and also with C/H/N content of the cells.
- the typical production process comprises of cells cultured in liquid medium at about 25 °C to 35 °C, under aerated condition.
- the design of fermentor is an important factor during the process optimization [Ellis S.B, et. al, Mol. Cell. Biol, 9, 1316-1323, (1985).; Villatte F, et. al, Appl. Microbiol Biotechnol, 55(4):463-5, (2001); Morganti L, et al, Biotechnol. Appl Biochem. 23:67 (1996); Stratton J, et al, Pichia Protocols, Higgins D.
- culture medium includes a suitable source for carbon such as glucose, glycerol, sucrose etc, assimilable nitrogen such as nitrates, NIL as ammonical liquor, yeast nitrogen base etc, along with vitamins such as vitamin B12, essential amino acids such as histidine, biotin, methionine etc, mineral supplements and trace metals such as manganese, mercury, iron and molybdenum salts, phosphates, sulfates etc.
- Suitable carbon sources include compounds, such as glycerol, glucose, fructose and the like, preferably glycerol.
- carbon source can include lower alcohols such as methanol, ethanol, propanol, isopropanol, butanol, isobutanol, and the like, preferably methanol.
- the examples of which include aqueous solution or syrups made using glucose or fructose, preferably aqueous solution.
- Glycerol may be used as the sole carbon source or 40 % of glycerol can be mixed with aqueous solution containing other nutrients required by the yeast.
- Alcohol content of the media can range from about 0.1 % to about 3 %.
- medium can contain alcohol about 0.5 %, 1 %, 2 %, or 3 %.
- the fermentation is preferably conducted in a manner that the carbon source is a growth- limiting factor and thereby providing good conversion of the carbon source into higher cell mass buildup.
- the assimilable nitrogen can be supplied using any nitrogen containing compounds capable of releasing nitrogen in a form that can be utilized by the yeast.
- the examples of nitrogen source includes organic or inorganic substances such as ammonium salts, nitrates, corn steep liquor, peptone, casein, meat extracts, bean-cakes, potato extracts, protein hydrolysates, yeast extract, urea, ammonium hydroxide and the like more preferably aqueous ammonia solution.
- the media can also contain high level of inorganic salts, such as magnesium, maganese, copper, sodium, molybdenum, zinc, iron, potassium, calcium sulfate, phosphoric acid, orthophosphoric acid, sulfuric acid, boric acid and the like; vitamins such as biotin, thiamine and the like; protease inhibitors; amino acids such as histidine and the like; along with other trace nutrients and metals.
- the medium can be supplemented with acid hydrolyzed casein (e.g., casamino acids or amicase) if desired to provide an enriched medium.
- media can also contain yeast's processing additives, growth-promoting factors, etc.
- the pH range in the aqueous microbial ferment may be in the range of 4 to 7, preferably around 4.5 to about 6.5.
- the preferred temperature during the fermentation is around 25°C-30°C, preferably around 30°C.
- the Pichia yeast requires aerobic conditions for growth, hence dissolved oxygen is required at all times during the fermentation. This may include supply of molecular oxygen in the form of air, oxygen enriched air or pure molecular oxygen itself so as to maintain the ferment with sufficient dissolved oxygen necessary to assist growth of cell.
- the overall aeration rates may vary from about 0.3 to 1.0 WM (volume air per volume of ferment per minute).
- the level of dissolved oxygen in the culture medium may vary from a minimum of about 1 % to about 100 % saturation, more preferably about 30 % to about 80 % saturation, and most preferably about 20 - 60 % saturation.
- the dissolved oxygen concentration may vary during the initial stages depending upon agitation (stirrer speed) in the fermentor.
- a fed batch fermentation protocol may be suitably modified. This may involve addition of suitable nutrients and carbon source. Alternatively, the batch can be modified by supplying booster feed of suitable nutrients from external source.
- protein production may be induced using the suitable alcohol, selected from the group consisting of methanol, ethanol, propanol, isopropanoL, butanol, and isobutanol, preferably methanol.
- suitable time for starting the production phase can be between 48 to 110 hours of cell growth and the biomass achieved is approximately 100 to 200 g/L of wet weight.
- Induction of protein production is started by addition of methanol.
- Methanol is added in the concentration range of about 0.6 to 3.0 % v/v preferably 0.8 to 2.8 % v/v, which is monitored by gas chromatography.
- the production medium feed may deliver methanol in neat form or the alcohol may be diluted initially with suitable amounts of water or trace metal solution.
- glycerol may be provided for a short time to retain metabolic activity of the cells.
- a medium may contain 1 to 2 % v/v methanol at the start of production phase of fermentation process.
- Production phase is monitored every 4-6 hours by sampling and examining various parameters which includes pH, OD, methanol concentration and increase in the concentration of the desired protein.
- Addition of methanol is controlled accordingly.
- Continuous or periodic addition of methanol is then started when the methanol concentration decreases to about 0.5 % v/v or less, and for example, 0.2 to 0.5% v/v.
- the continuous addition may be started, and continued till methanol concentration of 2.0 to 3.0 % v/v is attained.
- the promoter is induced by methanol causing expression of the target gene, which encodes for IFN alpha 2b protein in the present invention.
- the added methanol may be partly used for the growth of the microorganisms.
- the preferred embodiment of this invention involves addition of medium or extra nitrogen source prior to induction, which may lead to growth of the microorganisms simultaneous to the protein production, over at least a certain period of time.
- the present invention contemplates methods for producing a peptide or polypeptide in transformed Pichia, under the control of an alcohol-inducible promoter.
- Various fermentation protocols used to prepare high-density Pichia culture are outlined below and described in detail in the examples. In one of the embodiments of the invention, fermentation was carried as fed batch as follows:
- additional nitrogen source may be supplemented during growth stage.
- culture media may be varied and may include defined salt media to grow the recombinant Pichia pastoris KM 71 ZIF 2.2/14, for expression of IFN alpha 2b as follows:
- the present invention provides methods for producing a recombinant IFN alpha 2b by recombinant Pichia pastoris KM 71 ZIF 2.2/14 comprising of the following steps:
- the fermentation medium (described in Table 1) is inoculated with a culture of recombinant Pichia pastoris containing Interferon alpha 2b gene in the presence of all required nutrients, oxygen, carbon and nitrogen source and all parameters of temperature, pH, dissolved oxygen are maintained as described in the embodiment and specified in the examples illustrated below to obtain high cell density and high yield of the desired protein in the fermentation broth.
- the protein is isolated by conventional methods, either from the medium if the protein is secreted, or from the cells if it is not.
- the common practices for minimizing the proteolytic degradation include saturating proteases by adding casamino acids or peptone to the culture medium and / or counteracting neutral proteases by reducing the pH level of the culture medium to about 3.0 [Gellissen G, et al. Gene Expression in Recombinant Microorganisms, Smith (ed.), Marcel Dekker Inc., 195-239 (1994); (US 4,775,622,).].
- Peptone 20 g, Yeast Extract 10 g, Glycerol 10 ml, and phosphate buffer 0.5 M, pH 6.0 (100 ml) was added to each liter of medium prepared. After autoclaving 2 ml/L of biotin and histidine was added from stock solution.
- Peptone 200 g, Yeast Extract 100 g, Propylene Glycol 400 ml, antifoam (10 % dilution) 20 ml and phosphate buffer 1.0 M, pH 6.0 (500 ml), was added to each liter of medium prepared. After autoclaving 2 ml/L of biotin and histidine was added from stock solution.
- composition of trace metal solution A was Copper sulfate.5H 2 O 3.0 g, Maganese sulfate. 2H 2 O 3.0 g, Sodium Molybdate 0.2 g, Boric acid 0.02 g, Zinc chloride 4.0g and Sulfuric acid 5.0 ml.
- composition of trace metal solution B was ferrous sulfate 5 g, and 2-3 drops of sulfuric acid.
- Peptone 20 g, Yeast Extract 10 g, YNB without amino acid 6.7 g, Glycerol 20 ml and phosphate buffer 0.5 M, pH 6.0 (100 ml) was added to each liter of medium prepared. After autoclaving 2 ml L of biotin and histidine was added from stock solution.
- Peptone 20 g, Yeast Extract 10 g, Dextrose 20 g, and agar agar 20 g (pH 4.5) was added to each liter of medium prepared.
- Peptone 200 g, Yeast Extract 100 g, and phosphate buffer 0.5 M, pH 6.0 to make up one liter of medium. After autoclaving 20 ml/L of biotin and histidine was added from stock solution.
- Biotin (2.0 g / L), Histidine (4.0 g / L), Ammonia (25% v/v 500 ml), Antifoam (10 % v/v 500 ml),
- secreted proteins can have purity anywhere in between 20 - 50 %.
- the expressed polypeptide can be further purified to 90 % purity; or even greater than 95 % purity with respect to contaminating macromolecules, particularly other proteins, nucleic acids, and other infectious and pyrogenic agents.
- Polypeptides expressed by methylotrophic yeast may also be purified to a pharmaceutically pure state, which is greater than 99.0 % pure.
- solubility difference examples of which include methods such as salting out, precipitation with solvents
- differences in molecular size or weight examples include dialysis, ultrafiltration, gel filtration and SDS-polyacrylamide gel electrophoresis
- difference in the electric charge examples include ion-exchange chromatography
- methods utilizing specific affinity examples include affinity chromatography
- affinity chromatography examples include affinity chromatography
- methods utilizing a difference in the hydrophobic property examples include reversed- phase high-performance liquid chromatography or Hydrophobic Interaction Chromatography
- vi) methods utilizing a difference in the isoelectric point examples include isoelectric electrophoresis, etc.
- the present invention is concerned with production and purification of homogeneous IFN alpha 2b using chromatographic techniques particularly ion exchange and concentrating the purified protein by ultrafiltration.
- the present invention aims to provide a large- scale protein purification process to achieve high degree of purity in an economical way.
- Suitable chromatographic media include derivatized ' dextrans, agarose, cellulose, polyacrylamide, specialty silicas and the like, including PEI, DEAE, QAE, and Q derivatives.
- chromatographic media examples include those media derivatized with phenyl, butyl, or octyl groups, such as Phenyl-Sepharose FF (Pharmacia), Toyopearl butyl 650 (Toso Haas, Montgomeryville, Pa.), Octyl-Sepharose (Pharmacia) and the like, or polyacrylic resins, such as Amberchrom CG 71 (Toso Haas) and the like.
- Phenyl-Sepharose FF Phenyl-Sepharose FF (Pharmacia), Toyopearl butyl 650 (Toso Haas, Montgomeryville, Pa.), Octyl-Sepharose (Pharmacia) and the like
- polyacrylic resins such as Amberchrom CG 71 (Toso Haas) and the like.
- Suitable solid supports include glass beads, silica- based resins, cellulosic resins, agarose beads, cross-linked agarose beads, polystyrene beads, cross- linked polyacrylamide resins and the like that are insoluble under the conditions in which they are to be used.
- these supports can modify these supports with reactive groups such that proteins can link with amino, carboxyl, sulfhydryl, hydroxyl and/or carbohydrate moieties from the protein.
- the free protein can be converted into a salt thereof by known methods or method analogous thereto.
- the protein salt can be converted into a free form or into any other salt thereof by known methods or method analogous thereto.
- the suitable buffer solution may contain a protein-denaturing agent such as urea or guanidine hydrochloride or a surfactant such as Triton X-100 TM.
- the process of this invention preferably elutes the interferon from ion exchange column by increasing the pH.
- pH increase can be obtained by applying a buffer solution to the column.
- Such process may involve applying a solution of the said crude interferon onto a column, such as eluting the adsorbed interferon from said column using a buffer solution, wherein suitable known techniques of the chromatography may be used, which may include for example salt gradient or pH; concentrating the eluate obtained from previous step in a suitable way;
- the purification process was carried out according to the following schemes: Scheme 1: a) reconditioning of the supernatant by dilution, pH adjustment, and filtration; b) applying a solution of said crude interferon onto cation exchange column, preferably using a weak cation exchange such as carboxy methyl column (CM Sepharose FF, Amersham Biotech, Sweden.) and eluting the adsorbed interferon from said column using aqueous buffer solution; c) applying the
- Scheme 2 a) reconditioning of the supernatant by dilution, pH adjustment, and filtration; b) applying a solution of said crude interferon onto cation exchange column, preferably using a weak cation exchange such as carboxy methyl column (CM Sepharose FF, Amersham Biotech, Sweden.) and eluting the adsorbed interferon from said column using aqueous buffer solution; c) applying the eluate resulting from above step (b) onto an anion exchange column, such as
- Scheme 3 a) reconditioning of the supernatant by dilution, pH adjustment, and filtration; b) applying a solution of said crude interferon onto cation exchange column, preferably using a weak cation exchange such as carboxy methyl column (CM Sepharose FF, Amersham Biotech, Sweden.) and eluting the adsorbed interferon from said column using aqueous buffer solution containing EDTA; c) applying the eluate resulting from above step (b) onto an anion exchange column, such as DEAE or Q Sepharose FF (Amersham Biotech, Sweden.) and eluting the adsorbed interferon from said column using a different aqueous buffer solution containing EDTA; d) concentrating the eluate resulting from step c) by ultrafiltration provided with membrane of pore size 10,000 Dalton molecular cut off; e) passing the concentrated protein resulting from step d) through gel filtration column, wherein the said column is equilibrated with buffer
- Scheme 4 a) reconditioning of the supernatant by dilution, pH adjustment, and filtration; b) applying a solution of said crude interferon onto cation exchange column, preferably using a weak cation exchange such as carboxy methyl column (CM Sepharose FF, Amersham Biotech, Sweden.) and eluting the adsorbed interferon from said column using aqueous buffer solution containing EDTA; c) applying the eluate resulting from above step (b) onto an anion exchange column, such as DEAE or Q Sepharose FF (Amersham Biotech, Sweden.) and eluting the adsorbed interferon from said column using a different aqueous buffer solution containing EDTA; d) Eluated aqueous solution from step c) containing IFN alfa 2b captured on to the Hydrophobic Interaction Chromatography column and eluted out using third aqueous buffer.
- a weak cation exchange such as carboxy methyl column (
- step e concentrating the eluate resulting from step d) by ultrafiltration provided with membrane of pore size 10,000 Dalton molecular cut off; f) passing the concentrated protein resulting from step e) through gel filtration column, wherein the said column is equilibrated with buffer containing Tween-80 and EDTA to obtain homogeneous IFN alpha 2b.
- IFN alpha 2b The total protein content was determined according to the Bradford's method. Determination of specific protein, IFN alpha 2b was carried out by gel densitometry using Strategene Eagle Eye Video documentation system. Purity of IFN alpha 2b protein was determined by RP-HPLC using YMC protein RP column.
- the highly purified human interferon alpha 2b may be further used for making crystals, to prepare depot formulations [ eichert P, et al, US 5,741,485 (1998);].
- depot formulations [ eichert P, et al, US 5,741,485 (1998);].
- two forms of crystalline human interferon alpha 2 have been reported [Nagabhushan T. L. and Trotta P. P, Ulhnann's Encyclopedia of Industrial Chemistry, A14, VCH, Weinheim, Federal Republic of Germany 372-374 (1989); Miller D. L, et al. Science. 215, 689-690 (1982); Weissmann C, Interferon, Ion Gresser, ed. Academic Press, New York, 101-134 (1981); Nagabhusban T.
- the purified protein of the present invention has been characterized for its physicochemical, immunological and biological characteristics as follows: Molecular weight and purity determination by SDS-PAGE: The said protein has been resolved on SDS-PAGE and stained with coomassie blue as described by Oakley et al [150]. The results are summarized in FIG. 7 demonstrating its purity and molecular weight to be -19. 268 kDa. Isoelectro focussing of UN alpha 2b protein (Fig. 9):
- the pi of IFN alpha 2b protein of the present invention was determined by DBF (Oakley B. R, et al. Anal. Biochem, 105: 361 (1980)]) and was found to be ⁇ 5.3 which is the expected pi range of human IFN alpha 2b protein (Ref. Methods in Enzymology Vol. 119; 1986 "Interferon standards and general abbreviations.” S. Pestaka.).
- LCMS of IFN alpha 2b protein (Fig. 10):
- Type I interferons exhibit potent antiviral properties. Type I interferons also exhibit potent anticellular proliferation activity and immunomodulatory activity. IFN alpha have shown to inhibit various types of cellular proliferation. IFN.alpha.'s are especially useful against hematologic malignancies such as hairy-cell leukemia (Quesada, et al, 1984). Further, these proteins have also shown activity against multiple myeloma, chronic lymphocytic leukemia, low-grade lymphoma, Kaposi's sarcoma, chronic myelogenous leukemia, renal-cell carcinoma, urinary bladder tumors and ovarian cancers (Bonnem, et al, 1984; Oldham, 1985).
- interferons and interferon receptors have also been investigated (Benoit, et al, 1993). IFN.alphas are also useful against various types of viral infections (Finter, et al, 1991). Alpha interferons have shown activity against human papillomavirus infection, Hepatitis B, and Hepatitis C infections (Finter, et al, 1991; Kashima, et al, 1988; Dusheiko, et al, 1986; Davis, et al, 1989).
- interferons may be used to treat autoimmune, inflammatory, proliferative and hyperprohferative diseases, as well as cutaneous manifestations of immunologically mediated diseases.
- methods of the present invention are advantageous for treating conditions relating to immune system hypersensitivity [Johnson H. M, et al, USP 6,204,022 (2001).].
- Autoimmune diseases particularly amenable for treatment using the methods of the present invention include multiple sclerosis, type I (insulin dependent) diabetes mellitus, lupus erythematosus, amyotrophic lateral sclerosis, Crohn's disease, rheumatoid arthritis, stomatitis, asthma, uveitis, allergies and psoriasis [Johnson H. M, et al, USP 6,204,022 (2001).].
- Interferon alpha 2b of the present invention can be used, either singularly or in combination with other therapies as is known in the art for the treatment of any of the above mentioned therapeutic conditions.
- Pharmaceutical Compositions are provided, either singularly or in combination with other therapies as is known in the art for the treatment of any of the above mentioned therapeutic conditions.
- IFN alpha 2b of the present invention can be formulated according to known methods for preparing pharmaceutically useful compositions. Formulations comprising interferons have been previously described (for example, Martin, 1976). In general, the compositions of the present invention will be formulated such that an effective amount of the interferon is administered.
- compositions used in these therapies may also be in a variety of forms. These include, for example, solid, semi-solid, and liquid dosage forms, such as tablets, pills, powders, liquid solutions or suspensions, liposomes, suppositories, injectable, and infusible solutions. The preferred form depends on the intended mode of administration and therapeutic application.
- the compositions also preferably include conventional pharmaceutically acceptable carriers and adjuvants, which are known to those skilled in the art.
- the compositions of the invention are in the form of a unit dose and will usually be administered to the patient one or more times a day.
- the IFN.alpha 2b of the present invention may be administered to a patient in any pharmaceutically acceptable dosage form, including but not limited to oral intake, inhalation, intranasal spray, intraperitoneal, intravenous, intramuscular, intralesional, or subcutaneous injection.
- Interferon alpha protein solution formulations as mentioned in US 5,766,582 (Schering Plough) describes a process for making stable aqueous solution, formulations containing Alfa-type interferon for e.g. IFN alpha 2a and IFN alpha 2b, a phosphate buffer between pH range 6.6 to 7, Tween-80 as a stabilizer, EDTA as chelating agent, NaCl as a tonicity agent and m-cresol as an antimicrobial agent which maintain high chemical, physical and biological stability of the IFN alpha for an extended storage period of atleast 24 months. The same is included in this invention by way of reference.
- US 4,496,537 (Schering Corp.) describes a process for formulation of IFN alpha in lyophilized form wherein phosphate buffer of pH 6.8 to 7.0 containing 2.0 mg % glycine and 0.1 gm % HSA is used to lyophiUze IFN alpha at concentration of 7.5 x 10 I0 LU. per litre. Protein was found to be stable retaining biological activity for longer time. This is also incorporated by way of reference in the present invention.
- EP 0809996 A2 (Hof&nan-La-Roche) describes a process for physiologically active PEG- IFN alpha conjugates and the process for Pegylation of IFN alpha protein which are also included as reference.
- Pichia pastoris strain KM 71 was used as host strain, for transformation with the vector.
- the transformed Pichia host of present invention contained an expression vector prepared from pPICZalpha A (Invitrogen Corporation) which will be referred to as ZBT-alpha A hereinafter. This vector was ligated with modified human interferon alpha 2b gene after double restriction digestion with Xhol + Not! or EcoRI + Notl.
- the so obtained modified IFN alpha 2b clone was used further for cloning of mature human IFN alpha 2b gene using Xho I + Xba I or Xho I + Not I restriction sites.
- the fermentation process involved multiple approaches to obtain high-density cell culture described in this document.
- the IFN alpha 2b protein secreted is isolated and purified using simple techniques as described elsewhere in the document.
- EXAMPLE 1 Isolation of modified human IFN alpha 2b gene:
- the purified mRNA was used to prepare first strand of DNA by RT-PCR technique.
- the reaction mixture contained 500 nanograms mRNA, 50 units RNAse inhibitor, 20 units AMV reverse transcriptase, dNTP mix and oligo dT 17 in a 20 ⁇ l reaction volume and was incubated at 42 °C for 60 min.
- double stranded DNA was prepared using novel primers which are as described in Table 2, preferably with seq.
- the reaction mixture consists of cDNA synthesized above, along with 150 nM of each primer (SEQ ID 4+5 or 6+7), 150 ⁇ M of dNTP mixture and 1.5 mM MgCl 2 in PCR reaction buffer and PCR amplification was carried as usual.
- the product obtained was resolved on 1 % agarose gel containing ethidium bromide in 1 x TAE buffer at 50 V for 2 hrs.
- EXAMPLE 2 Cloning of modified IFN alpha 2b gene in E. coli JM109:
- the M13mpl8 plasmid found in E. coli was isolated from 2.0 ml of overnight cultures grown at 37°C using known method [Westermeier, R. Electrophoresis in Practice, 2 nd Ed, VCH, Winheim, Germany (1997).].
- the plasmid DNA was resolved on 1.5 % agarose gel and quantified. The size of the inserts was determined by digestion with restriction endonucleases Hinc II and later was verified for purity and quantified.
- the dephosphorylated linearized M13mpl8 plasmid was ligated with the cDNA obtained in Example 1.
- the ligation reaction contained the above two in 1:3 ratio and 3 units of T4 DNA ligase, 1 x ligation buffer and 1 mM riboATP in 20 ⁇ l of reaction mixture.
- This ligated construct was transformed in E.coli JM 109 competent cells by CaCl 2 method [Ref. Methods in Enzymology Vol. 119; 1986 "Interferon standards and general abbreviations.” S. Pestaka.].
- the transformants were grown on Luria agar containing X-gal and IPTG, from which 20 white recombinant plaques were isolated and named as GAS 8W1 through GAS 08W20,GAS being the code given for modified IFN alfa 2b gene of the present invention.
- the RF DNA was isolated from recombinant E.coli (GAS 08 W2) and 2 to 5 ⁇ g of RF DNA was subjected to double restriction digestion.
- the reaction mixture had 2 units each of EcoRl and Hind UI restriction enzymes, 1 x universal buffer in 50 ⁇ l solution and was incubated at 37 °C for 4 to 5 hrs.
- the product was resolved on 1 % agarose gel having 0.5 ⁇ g/ml of ethidium bromide.
- the size of the released fragment was confirmed as -580 bp when compared with standard molecular weight markers. This fragment henceforth was called GAS 2b gene, was purified by using QIA quick gel extraction kit (Qiagen) as per manufacturer's instructions.
- the expression vector pPICZ alpha A was obtained from Invitrogen Corporation (here after called ZBT alpha A) and propagated in E. coli TOP 10F'.
- the plasmid DNA was isolated by alkali lysis method [Westermeier, R. Electrophoresis in Practice, 2 nd Ed, VCH, Winheim, Germany (1997)].
- the modified GAS 2b gene was amplified using primers, having seq. ID Nos. 8 & 9 and 10 & 11 as forward & reverse primers, which are described in Table 2.
- the GAS 2b gene from GAS 08W2 DNA was reamplified.
- the reaction mixture contained 100 nM of template GAS 08W2 DNA, 1 x PCR buffer, 1.5 mM MgCl 2 , 150 ⁇ M dNTP mixture, 150 nM of each primer and 2 units of Taq polymerase (MBI Fermentas) according to previously described procedure.
- An aliquot of amplified DNA was resolved on 1.5 % agarose gel containing 0.5 ⁇ g / ml of ethidium bromide along with the standard 1 kb ladder marker (MBI Fermentas).
- the ZBTalpha A vector was restriction digested (in separate reactions) using Xho 1+ Not I; EcoRI + Not I, 1 x universal buffer in 50 ⁇ l solution.
- the purified cDNA was ligated to ZBTalpha A vector DNA.
- This ligated DNA was then used to transform E. coli TOP 10F' by electroporation method.
- the competent E coli cells were mixed with - 100 ng of purified ligated DNA in chilled electroporation cuvette and cells were transformed using Electroporetor 1000 (Strategene) [Gressen I ed, "Interferons, 1979" Academic Press, New York;].
- E coli ZBT- IFMB 1, 2, 3 — The transformants, (hereinafter called E coli ZBT- IFMB 1, 2, 3 — ) were verified for the presence of the modified GAS 2b gene as described before. The orientation of the GAS 2b gene was confirmed by using the combination of vector specific and gene specific primers.
- the positive clones or the recombinant clones having the modified IFN alpha 2b gene were called E coli ZBT- IFMBl, 2, 3. and E coli ZBT- IFMB3 clone was sequenced using the dideoxy termination method.
- the sequence data was of modified interferon alpha 2b gene ⁇ Fig No. 1 - SEQ ID No. 1 ⁇ .
- EXAMPLE 4 Cloning of IFN alpha 2b gene in R coli TOP 10 F':
- the modified IFN alpha 2b clone ZBT-IF MB3 of EXAMPLE 3 was further used for cloning of human interferon alpha 2b of this invention. Plasmid DNA was isolated from the clone using Wizard Plus SV Miniprep DNA purification system (Promega). This DNA was then restriction digested using Xho 1+ Not I or EcoRI + Not I enzymes, 1 x universal buffer in 20 ⁇ l solution to release the cloned modified IFN alpha 2b fragment.
- This fragment was purified from the gel using QIAquick Gel Extraction Kit (QIAGEN) and used as a template for PCR amplification of human IFN alpha 2b of this invention with Primers having SEQ ID 12 & 13 or SEQ ID 12 & 14 as forward and reverse primers.
- the reaction mixture contained the above DNA as template, 1 x PCR buffer, 1.5 mM MgCl 2 , 150 ⁇ M dNTP mixture, 150 nM of each primer and 3 units of Taq polymerase (MBI Fermentas) according to previously described procedure.
- An aliquot of amplified DNA was resolved on 1.0 % agarose gel containing 0.5 ⁇ g / ml of ethidium bromide along with the standard 1 kb ladder marker (MBI Fermentas).
- ZBTalpha A vector was restriction digested (in separate reactions) using Xho I
- E. coli TOP 10F' DNA was then used to transform E. coli TOP 10F' by electroporation method.
- the competent E coli cells were mixed with - 100 ng of purified ligated DNA in chilled electroporation cuvette and cells were transformed using ⁇ lectroporetor 1000 (Strategene) [Gressen I ed, "Interferons, 1979" Academic Press, New York;] .
- the transformed cells were plated on a low salt Luria agar containing 25 ⁇ g/ml each of Zeocin and Tetracycline, plates were incubated at 37°C overnight.
- the transformants (hereinafter called E coli ZBT-IF 2.1, 2.2, 2.3 — ) were verified for the presence of the IFN alpha 2b gene as described before. (Fig. 4,5)
- the orientation of the IFN alpha 2b gene was confirmed by using the combination of vector specific and gene specific primers.
- the positive transformant having the right orientation was used for further sub cloning in Pichia pastoris KM71 strain.
- the positive clone or the recombinant clone having the IFN alpha 2b gene was called E coli ZBT- IF 2.2 and this clone was sequenced using the dideoxy termination method.
- the sequence data confirmed that the gene is novel, interferon alpha 2b gene ⁇ Fig No. 2b - S ⁇ Q ID No. 3 ⁇ .
- Transformation of yeast Pichia pastoris KM 71 was carried out according to method described in literature using LiCl [Higgins D. R, and Cregg J. M, (eds.), Pichia Protocols, Methods in Molecular Biology, Humana Press, (Totowa, NJ), 103: 249-261 (1998).].
- a single isolated colony of Pichia pastoris KM 71 was grown in 10 ml of YPD media (Table IF). The cells were harvested, washed twice with distilled water and suspended in 10 ml of 100 mM LiCl. Competent cells were recovered by brief centrifugation. Yeast pellet was mixed with 240 ⁇ l of 50 % PEG, 36 ⁇ l of 1 M LiCl, 25 ⁇ l of 2 mg / ml SS DNA and 50 ⁇ l of the linearized insert (1-10 ⁇ g) and construct was introduced into yeast cell by heat shock.
- the transformed cells were plated on selective agar plates (YPD agar containing Zeocin antibiotic) and incubated for 2 to 4 days at 30°C. Twenty five transformants / clones were selected and PCR analysis was done using their genomic DNA to determine integration of IFN alpha 2b gene into the Pichia genome (FIG.6). These twenty five transformants/ clones were then screened for the production of the IFN alpha 2b protein at shake flask level. These clones were named as Pichia pastoris ZIF clone 2.2/1 - 2.2/25 EXAMPLE 6: Development of inoculum using BGYP medium for fermentation process:
- BGYP medium composition Table 1
- the flask was incubated at 30 + 0.5° C, on rotary shaker at about 210 rpm, with 1" displacement for 24-48 hours.
- 2 % v/v of the above inoculum was further diluted in 200 ml BGYP medium into a IL flask, which was incubated for about 48-72 hrs on rotary shaker under the similar conditions.
- the inoculum prepared was used for fermentation and production of desired protein.
- EXAMPLE 7 Development of inoculum using BGY medium for fermentation process. In another method, the inoculum was developed using BGY medium. To the medium biotin and histidine stock solutions were added (0.4 mg / L of biotin and 8 mg / L of histidine was present in the medium).
- the seed stage I was initiated by inoculating 50 ml BGY medium with 1 ml of thawed glycerol stock of Pichia pastoris ZIF 2.2/14 stored at - 70° C, under aseptic condition.
- the flask was incubated at 30 + 0.5 °C for about 48 hours on rotary shaker at about 210 rpm, with 1" displacement. After 24-48 hrs of fermentation, the purity of seed was confirmed by microscopy.
- 200 ml BGY contained in a 1 L Erlenmeyer flask was inoculated with 2 % v/v concentration of cells from seed stage 1. This seeded flask was incubated on rotary shaker and cultivated under similar conditions. The inoculum prepared was used for fermentation to produce IFN alpha 2b protein.
- the fermentation process was carried out under submerged aerobic conditions.
- the fermenter was equipped with automatic pH, temperature and dissolved oxygen controls.
- 20 L fermenter 8 to 10 L of complex medium was prepared, sterilized and inoculated with the inoculum prepared as described in example 6 or 7.
- the agitation rate varied between 230 to 450 rpm.
- the aeration rates varied from about 0.4 to 1.0 volume (at about atmospheric pressure and about 25° C) per volume of ferment per minute of air supplied.
- the air supplied was mixed with sufficient oxygen whenever required, in order to maintain dissolved oxygen at about 20 to 60 % saturation.
- the complex media used in the present fermentation process was prepared as described in Table 1A, after sterilization the media was further supplemented with 2 ml/L each of biotin and histidine stock solutions.
- the stock biotin and histidine solutions were prepared (Table 1), filter- sterilized and stored at +4 °C.
- the fermentation was carried out at 30 °C at about atmospheric pressure in fed batch protocol, wherein glycerol was added (10 ml/L of complex media) in rate limiting concentration and was later slowly increased.
- glycerol was added (10 ml/L of complex media) in rate limiting concentration and was later slowly increased.
- the cells were separated by centrifugation at 6000-8000 g, and resuspended in 10 litre of BMY medium (described in Table IB).
- the cells were transferred back to the fermenter, under aseptic conditions.
- the cells were induced by methanol (50 % aqueous solution), wherein the concentration of methanol was maintained between 0.7 to 2.7 % v/v, by measuring the methanol content in the ferment by gas chromatography. Multiple induction were carried out.
- the concentration of expressed r-human IFN alpha 2b protein obtained was - 5 200 mg/L as monitored by densitometric analysis of commassie blue stained SDS-PAGE gel
- a continuous aerobic fermentation process was carried out in a fermenter as described in
- a defined soluble salt media (Table ID) was used.
- twenty litre fermenter having 10 litre of defined salt medium having composition described in Table ID was prepared, and trace metal solution A and B were added to this and pH was adjusted to 3.5.
- the medium was sterilized in fermenter at 121 °C for 30 min. After sterilization, pH of the medium was adjusted to 5.0 with sterile ammonium hydroxide solution and
- the culture was stirred continuously by passing air supplemented with sufficient oxygen to maintain dissolved oxygen level at about 20 - 60 % of saturation.
- Aqueous ammonium hydroxide was also added at a rate so as to maintain the pH of the fermentation mixture at about 5 3.5 to 4.5.
- the fermentation was carried out at 30 °C and at atmospheric pressure.
- the pH was maintained in the range of 3.5 to 4.5 initially and increased gradually, from about 3.0 - 3.5 to 4.5 - 5.0 at the end of fermentation.
- Glycerol feed was started initially at 1 ml IU hr rate and later increased to a maximum of upto 20 ml / L / hr. After 62 to 64 hours (including a starvation period of at least two hours), the cells were induced by methanol.
- the fermentation process was monitored by densitometric analysis of coommassie blue stained SDS-PAGE gel of fermentation samples run along with the known standard. It was
- the fermentation process was initiated in a fed batch mode as described in previous example 10, except modification of glycerol feed rate which varied from 0.3 ml / L / hr to 20ml / L
- the fermentation process was initiated as described in previous example 11. At the end of growth stage and additional starvation period of 0.5-1 hour, 1 liter of 10X BMY was added to the fermenter.
- the induction was initiated by addition of filter sterilized methanol solution (50 % v/v aqueous methanol containing 6 ml / L each of trace metal solution PTM A and PTM B ) to maintain methanol concentration of about 1.5 to 3.0 % v/v. Further addition or subsequent induction was started when methanol concentration dropped to about 0.5 to 0.8 %.
- pH of fermentation was maintained at around 6.0 + 0.1 by addition of ammonia solution through pH controller.
- Levels of desired protein produced was monitored by densitometric analysis of coommassie blue stained SDS-PAGE gels of fermentation samples run along with known standard.
- the yield of IFN alpha 2b protein was - 550-600 mg / L of fermentation broth.
- EXAMPLE 13 Modified Batch Fermentation Process 5: The fermentation process was initiated in a fed batch mode as described in previous example 10, except modification of glycerol feed rate which varied from 0.3 ml/L/ hr to 20ml/L/hr during initial 78-108 hours of fermentation time. The fermentation was conducted at 30 °C and about atmospheric pressure. The pH, dissolved oxygen, agitation rates were maintained similar to that in example 10. At the end of growth stage, the cells were separated by centrifugation at 6000-8000 g, and resuspended in 10 liter of BMY medium (described in Table IB).
- Step A The supernatant containing recombinant IFN alpha 2b protein was separated from the fermented broth by centrifugation at 6000-8000 g for 10 min at 4-8 °C. Supernatant was cooled to 8-10 °C, and diluted 1:1 volume with Milli Q water. The pH of solution was adjusted to
- Step C The eluant obtained in step B, which is containing IFN alpha 2b protein, was diluted 10 times with Milli Q water and pH was adjusted to 6.3-7.3. This material was directly loaded on pre-equilibrated anion exchange column (DEAE Sepharose FF or Q Sepharose FF (Amersham Biosciences)).
- Step D To the eluant obtained in step C, which contains IFN alpha 2b protein, was added ammonium sulfate to achieve a final concentration of 0.75 M-1.5 M, preferably 0.75 M to 1.2 M of ammonium sulfate and pH was adjusted to 6.3-6.8, more preferably 6.5-6.8.
- the solution containing IFN alpha 2b protein was filtered through 0.45 micron disc filter. The filtrate was directly loaded on pre-equilibrated HIC column (XK 50/200 mm) (Butyl Sepharose FF or Butyl Toyo (Amersham Biosciences /Toshohaas)).
- Step E The eluant from step D containing IFN alpha 2b, was concentrated 20 times by ultrafiltration using Amicon Stirred Cell (400 ml capacity) with YM 10 membrane (10,000 MWCO). The final concentration of IFN alpha 2b protein in retentate was - 15-20 mg / ml.
- Step F The gel filtration column was packed with Sephacryl HR 200/HR 100/Sephadex G 75/Sephadex G 25 cores (Pharmacia), equilibrated with gel filtration buffer (lOmM Ammonium acetate, containing 150 mM NaCl, 0.2% w/v EDTA, 0.2% v/v Tween - 80, and pH was adjusted to 5.0-5.5 with acetic acid).
- the concentrated BFN alpha 2b protein obtained in step E was loaded on this column. An isocratic elution was carried out using gel filtration buffer. The peak fraction containing pure homogenous IFN alpha 2b protein was collected and a sample was taken for SDS- PAGE analysis. Single band purity observed on SDS-PAGE (Coomassiae blue stain) analysis.
- EXAMPLE 16 Purification of recombinant IFN alpha 2b protein to homogeneity:
- Step A The supernatant containing recombinant IFN alpha 2b protein was separated from the fermented broth by centrifugation at 6000-8000 g for 10 min at 4-8 °C. Supernatant was cooled to 8-10 °C, and diluted 1:1 volume with Milli Q water. The pH of solution was adjusted to 5.2 and was filtered through 0.45 micron cartridge (Milliguard, Millipore Inc.) at low temperature.
- AIEX buffer II 150 mM
- Step D The eluant from step C containing IFN alpha 2b, was concentrated 20 times by ultrafiltration using Amicon Stirred Cell (400 ml capacity) with YM 10 membrane (10,000 MWCO). The final concentration of IFN alpha 2b protein in retentate was - 15-20 mg / ml.
- Step E The Versaflo Axial 9/60 Cm column (Sepragen Inc.) was packed with Sephacryl
- EXAMPLE 17 Purification of recombinant IFN alpha 2b protein to homogeneity:
- Step A The supernatant containing recombinant IFN alpha 2b protein was separated from the fermented broth by centrifugation at 6000-8000 g for 10 min at 4-8 °C. Supernatant was cooled to 8-10 °C, and diluted 1:1 volume with Milli Q water. The pH of solution was adjusted to 5.2 and was filtered through 0.45 micron cartridge (Milliguard, Millipore Inc.) at low temperature.
- Step B In the next step, Super flow radial 1500 column (Sepragen Inc.) was packed with weak cation exchanger CM Sepharose FF or SP Sepharose FF (Amersham Biosciences) (Bed volume 1500 ml) and pre-equilibrated with chilled CIEX buffer I (50-100 mM Ammonium
- Step C The eluant obtained in step B, which is containing IFN alpha 2b protein, was diluted 10 times with Milli Q water and pH was adjusted to 6.3-7.3. This material was directly loaded on pre-equilibrated on anion exchange column (DEAE Sepharose FF or Q Sepharose FF (Amersham Biosciences)).
- Step D To the eluant obtained in step C, which contains IFN alpha 2b protein, was added ammonium sulfate to achieve a final concentration of 0.75 M- 1.5 M, preferably 0.75 M to 1.2 M of ammonium sulfate and pH was adjusted to 6.3-6.8, more preferably 6.5-6.8.
- the solution containing IFN alpha 2b protein was filtered through 0.45 micron disc filter. The filtrate was directly loaded on pre-equilibrated HIC column (XK 50/200 mm) (Butyl Sepharose FF or Butyl Toyo (Amersham Biosciences /Toshohaas)).
- Step E The eluant from step D containing IFN alpha 2b, was concentrated 20 times by ultrafiltration using Amicon Stirred Cell (400 ml capacity) with YM 10 membrane (10,000 MWCO). The final concentration of IFN alpha 2b protein in retentate was - 15-20 mg / ml.
- Step F The gel filtration column was packed with Sephacryl HR 200/HR 100/Sephadex G 75/Sephadex G 25 cores (Pharmacia), equilibrated with gel filtration buffer (lOmM Ammonium acetate, containing 150 mM NaCl, 0.2% w/v EDTA, 0.2% v/v Tween - 80, and pH was adjusted to 5.0-5.5 with acetic acid).
- the concentrated IFN alpha 2b protein obtained in step E was loaded on this column. An isocratic elution was carried out using gel filtration buffer. The peak fraction containing pure homogenous IFN alpha 2b protein was collected and a sample was taken for SDS- PAGE analysis. Single band purity was observed on SDS-PAGE (Coomassiae blue stain) analysis.
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Gastroenterology & Hepatology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Toxicology (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
Description
Claims
Priority Applications (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/IN2002/000216 WO2004039996A1 (en) | 2002-11-01 | 2002-11-01 | Mthod for producing recombinant human interferon alpha 2b polypeptide in pichia pastoris |
EP02808074A EP1556498A1 (en) | 2002-11-01 | 2002-11-01 | Method for producing recombinant human interferon alpha 2b polypeptide in pichia pastoris |
AU2002356422A AU2002356422A1 (en) | 2002-11-01 | 2002-11-01 | Mthod for producing recombinant human interferon alpha 2b polypeptide in pichia pastoris |
US10/533,320 US20060223145A1 (en) | 2002-11-01 | 2002-11-01 | Method for producing recombinant human interferon alpha 2b polypeptide in pichia pastoris |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/IN2002/000216 WO2004039996A1 (en) | 2002-11-01 | 2002-11-01 | Mthod for producing recombinant human interferon alpha 2b polypeptide in pichia pastoris |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2004039996A1 true WO2004039996A1 (en) | 2004-05-13 |
Family
ID=32259855
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/IN2002/000216 WO2004039996A1 (en) | 2002-11-01 | 2002-11-01 | Mthod for producing recombinant human interferon alpha 2b polypeptide in pichia pastoris |
Country Status (4)
Country | Link |
---|---|
US (1) | US20060223145A1 (en) |
EP (1) | EP1556498A1 (en) |
AU (1) | AU2002356422A1 (en) |
WO (1) | WO2004039996A1 (en) |
Cited By (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2009113099A2 (en) | 2008-02-06 | 2009-09-17 | Biocon Limited | Fermentation medias and processes thereof |
WO2010075159A1 (en) | 2008-12-23 | 2010-07-01 | Schering Corporation | Purification of recombinantly produced interferon |
US20100261275A1 (en) * | 2007-12-10 | 2010-10-14 | Yves Durocher | Production of Recombinant Interferon Proteins |
US8466159B2 (en) | 2011-10-21 | 2013-06-18 | Abbvie Inc. | Methods for treating HCV |
US8492386B2 (en) | 2011-10-21 | 2013-07-23 | Abbvie Inc. | Methods for treating HCV |
US8809265B2 (en) | 2011-10-21 | 2014-08-19 | Abbvie Inc. | Methods for treating HCV |
US8853176B2 (en) | 2011-10-21 | 2014-10-07 | Abbvie Inc. | Methods for treating HCV |
CN104324365A (en) * | 2014-10-24 | 2015-02-04 | 孙二琳 | Preparation method of dry powder of recombinant human interferon-alpha-2b-BCG |
WO2015056125A1 (en) | 2013-10-15 | 2015-04-23 | Uab Biotechnologines Farmacijos Centras "Biotechpharma" | Fused proteins of interferon alpha 5 with another cytokine and a process for producing thereof |
CN105039188A (en) * | 2015-08-28 | 2015-11-11 | 广东海纳川生物科技股份有限公司 | Recombinant Pichia pastoris culture medium, and culture method and application thereof |
CN108277179A (en) * | 2018-03-07 | 2018-07-13 | 武汉光谷创赢生物技术开发有限公司 | A kind of high density fermentation and spray drying process of bacillus subtilis |
US11192914B2 (en) | 2016-04-28 | 2021-12-07 | Emory University | Alkyne containing nucleotide and nucleoside therapeutic compositions and uses related thereto |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20070231856A1 (en) * | 2003-05-30 | 2007-10-04 | Pei Ye | Recombinant Protein and Polypeptide Production Using Methylotropic or Ethylotropic Microorganisms with a Dilute Methanol or Ethanol Feeding |
CA2698173C (en) * | 2007-09-04 | 2015-02-03 | Biosteed Gene Expression Tech. Co., Ltd. | Interferon alpha 2b modified by polyethylene glycol, the preparation and use thereof |
WO2009030065A1 (en) * | 2007-09-04 | 2009-03-12 | Biosteed Gene Expression Tech. Co., Ltd. | INTERFERON ALPHA 2a MODIFIED BY POLYETHYLENE GLYCOL, ITS SYNTHESIS PROCESS AND APPLICATION |
CN116120424A (en) * | 2022-06-06 | 2023-05-16 | 江苏靶标生物医药研究所有限公司 | Interferon alpha 2b soluble recombinant expression and separation purification method and application thereof |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0032134A2 (en) * | 1980-01-08 | 1981-07-15 | Biogen, Inc. | DNA sequences, recombinant DNA molecules and processes for producing human interferon-alpha like polypeptides |
WO2001068827A1 (en) * | 2000-03-16 | 2001-09-20 | Shantha Biotechnics (P) Ltd. | A process for the production of human interferon alpha from genetically engineered yeast |
EP1236800A2 (en) * | 2001-03-01 | 2002-09-04 | GenOdyssee | Nucleic acids encoding interferon alpha 2, containing single nucleotide polymorphisms and methods of use thereof |
-
2002
- 2002-11-01 WO PCT/IN2002/000216 patent/WO2004039996A1/en not_active Application Discontinuation
- 2002-11-01 AU AU2002356422A patent/AU2002356422A1/en not_active Abandoned
- 2002-11-01 EP EP02808074A patent/EP1556498A1/en not_active Withdrawn
- 2002-11-01 US US10/533,320 patent/US20060223145A1/en not_active Abandoned
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0032134A2 (en) * | 1980-01-08 | 1981-07-15 | Biogen, Inc. | DNA sequences, recombinant DNA molecules and processes for producing human interferon-alpha like polypeptides |
WO2001068827A1 (en) * | 2000-03-16 | 2001-09-20 | Shantha Biotechnics (P) Ltd. | A process for the production of human interferon alpha from genetically engineered yeast |
EP1236800A2 (en) * | 2001-03-01 | 2002-09-04 | GenOdyssee | Nucleic acids encoding interferon alpha 2, containing single nucleotide polymorphisms and methods of use thereof |
Non-Patent Citations (5)
Title |
---|
DATABASE EMBL [online] 29 July 1991 (1991-07-29), GOEDDEL D ET AL.,: "Homo sapiens interferon alpha-a (IFNA) gene, complete cds.", XP002240746, Database accession no. J00207 * |
GARCIA J N ET AL: "HIGH LEVEL EXPRESSION OF HUMAN IFN-ALPHA2B IN PICHIA PASTORIS", BIOTECNOLOGIA APLICADA, LA HABANA, CU, vol. 12, no. 3, 1995, pages 152 - 155, XP002930567, ISSN: 1027-2852 * |
LEE N ET AL: "INTERFERON-ALPHA2 VARIANTS IN THE HUMAN GENOME", JOURNAL OF INTERFERON AND CYTOKINE RESEARCH, MARY ANN LIEBERT, NEW YORK, NY, US, vol. 15, no. 4, April 1995 (1995-04-01), pages 341 - 349, XP001016231, ISSN: 1079-9907 * |
LIU P T TA TUAN V VILLARETE L H: "High-yield expression and purification of human interferon alpha-1 in Pichia pastoris", PROTEIN EXPRESSION AND PURIFICATION, ACADEMIC PRESS, US, vol. 22, August 2001 (2001-08-01), pages 381 - 387, XP002954670, ISSN: 1046-5928 * |
STREULI M ET AL.,: "AT LEAST THREE HUMAN TYPE ALPHA INTERFERONS: STRUCTURE OF ALPHA2", SCIENCE, AMERICAN ASSOCIATION FOR THE ADVANCEMENT OF SCIENCE, US, vol. 209, 1980, pages 1343 - 1347, XP000605251 * |
Cited By (30)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20100261275A1 (en) * | 2007-12-10 | 2010-10-14 | Yves Durocher | Production of Recombinant Interferon Proteins |
US8927256B2 (en) | 2008-02-06 | 2015-01-06 | Biocon Limited | Fermentation medias and processes thereof |
JP2011510677A (en) * | 2008-02-06 | 2011-04-07 | バイオコン・リミテッド | Fermentation medium and process thereof |
US9255285B2 (en) | 2008-02-06 | 2016-02-09 | Biocon Limited | Fermentation medias and processes thereof |
CN101983242A (en) * | 2008-02-06 | 2011-03-02 | 拜康有限公司 | Fermentation media comprising urea-like nitrogen sources and its use for the production of secondary metabolits, enzymes and recombinant proteias |
KR101492011B1 (en) | 2008-02-06 | 2015-02-10 | 바이오콘 리미티드 | Fermentation medias and processes thereof |
CN101983242B (en) * | 2008-02-06 | 2015-12-16 | 拜康有限公司 | Fermention medium containing urea class nitrogenous source and the purposes for the production of recombinant protein thereof |
KR101283734B1 (en) * | 2008-02-06 | 2013-07-08 | 바이오콘 리미티드 | Fermentation medias and processes thereof |
RU2556120C2 (en) * | 2008-02-06 | 2015-07-10 | Байокон Лимитид | Fermentation medium and method of producing recombinant proteins |
RU2491345C2 (en) * | 2008-02-06 | 2013-08-27 | Байокон Лимитид | Fermentation medium and method of production of recombinant proteins |
WO2009113099A3 (en) * | 2008-02-06 | 2009-11-05 | Biocon Limited | Fermentation media comprising urea-like nitrogen sources and its use for the production of secondary metabolits, enzymes and recombinant proteias |
WO2009113099A2 (en) | 2008-02-06 | 2009-09-17 | Biocon Limited | Fermentation medias and processes thereof |
WO2010075159A1 (en) | 2008-12-23 | 2010-07-01 | Schering Corporation | Purification of recombinantly produced interferon |
US8969357B2 (en) | 2011-10-21 | 2015-03-03 | Abbvie Inc. | Methods for treating HCV |
US8685984B2 (en) | 2011-10-21 | 2014-04-01 | Abbvie Inc. | Methods for treating HCV |
US8680106B2 (en) | 2011-10-21 | 2014-03-25 | AbbVic Inc. | Methods for treating HCV |
US8809265B2 (en) | 2011-10-21 | 2014-08-19 | Abbvie Inc. | Methods for treating HCV |
US8993578B2 (en) | 2011-10-21 | 2015-03-31 | Abbvie Inc. | Methods for treating HCV |
US8853176B2 (en) | 2011-10-21 | 2014-10-07 | Abbvie Inc. | Methods for treating HCV |
US9452194B2 (en) | 2011-10-21 | 2016-09-27 | Abbvie Inc. | Methods for treating HCV |
US8492386B2 (en) | 2011-10-21 | 2013-07-23 | Abbvie Inc. | Methods for treating HCV |
US8466159B2 (en) | 2011-10-21 | 2013-06-18 | Abbvie Inc. | Methods for treating HCV |
WO2015056125A1 (en) | 2013-10-15 | 2015-04-23 | Uab Biotechnologines Farmacijos Centras "Biotechpharma" | Fused proteins of interferon alpha 5 with another cytokine and a process for producing thereof |
LT6164B (en) | 2013-10-15 | 2015-06-25 | Uab Biotechnologinės Farmacijos Centras "Biotechpharma" | Fused proteins of interferon alpha 5 with another cytokine and process for production thereof |
CN104324365A (en) * | 2014-10-24 | 2015-02-04 | 孙二琳 | Preparation method of dry powder of recombinant human interferon-alpha-2b-BCG |
CN104324365B (en) * | 2014-10-24 | 2016-03-16 | 孙二琳 | The dry powder doses preparation method of recombined human interferon-alpha-2b-BCG |
CN105039188A (en) * | 2015-08-28 | 2015-11-11 | 广东海纳川生物科技股份有限公司 | Recombinant Pichia pastoris culture medium, and culture method and application thereof |
US11192914B2 (en) | 2016-04-28 | 2021-12-07 | Emory University | Alkyne containing nucleotide and nucleoside therapeutic compositions and uses related thereto |
CN108277179A (en) * | 2018-03-07 | 2018-07-13 | 武汉光谷创赢生物技术开发有限公司 | A kind of high density fermentation and spray drying process of bacillus subtilis |
CN108277179B (en) * | 2018-03-07 | 2021-08-03 | 武汉生物样本库有限公司 | High-density fermentation and spray drying method of bacillus subtilis |
Also Published As
Publication number | Publication date |
---|---|
EP1556498A1 (en) | 2005-07-27 |
US20060223145A1 (en) | 2006-10-05 |
AU2002356422A1 (en) | 2004-05-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20060223145A1 (en) | Method for producing recombinant human interferon alpha 2b polypeptide in pichia pastoris | |
US7572437B2 (en) | Long acting human interferon analogs | |
US4929554A (en) | Human immune interferon | |
EP1789442B1 (en) | Muteins of fibroblast growth factor 21 | |
JP2662390B2 (en) | Insiulin analog | |
EP0744409B9 (en) | Platelet growth accelerator | |
EP0778893B1 (en) | Bacterial production of Interferon-beta polypeptide | |
US5096705A (en) | Human immune interferon | |
US6433142B1 (en) | Megakaryocyte stimulating factors | |
EP2270163A1 (en) | Muteins of fibroblast growth factor 21 | |
US5582824A (en) | Recombinant DES-CYS-TYR-CYS human immune interferon | |
JP2003508023A (en) | Immunoglobulin fusion protein | |
US20060051859A1 (en) | Long acting human interferon analogs | |
EP0170204A2 (en) | Genetic sequences, type I interferon peptide coded by them, and these organisms producing the same | |
Gomes et al. | Expression of recombinant human mutant granulocyte colony stimulating factor (Nartograstim) in Escherichia coli | |
CA2382425A1 (en) | Interferon tau mutants and methods for making them | |
JP2653061B2 (en) | Novel polypeptide and method for producing the same | |
US7311903B2 (en) | Glycosylated human interferon alpha isoform | |
EP0306870A2 (en) | Gamma-interferon derivatives, process for their manufacture, vectors and medicines obtained therefrom | |
EP2532734B1 (en) | Process for the production of interferon alpha 5 | |
WO2004019856A9 (en) | Glycosylated human interferon alpha isoform | |
IL90975A (en) | Non-glycosylated, recombinant human il2 in reduced form, the process for obtaining it and its use as a medicament | |
KR20040083268A (en) | Human granulocyte-colony stimulating factor conjugate having enhanced stability in blood and process for the preparation thereof | |
RU2764787C1 (en) | RECOMBINANT PLASMID DNA ENCODING CHIMERIC INTERFERON ALPHA2b, RECOMBINANT STRAIN OF YEAST P. PASTORIS X33 - PRODUCER OF CHIMERIC INTERFERON ALPHA2b, AND METHOD FOR PRODUCING THIS PROTEIN | |
CA2223749A1 (en) | Stable tpo-containing lyophilized compositions |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR IE IT LU MC NL PT SE SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2002808074 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 420/MUMNP/2005 Country of ref document: IN |
|
WWP | Wipo information: published in national office |
Ref document number: 2002808074 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2006223145 Country of ref document: US Ref document number: 10533320 Country of ref document: US |
|
NENP | Non-entry into the national phase |
Ref country code: JP |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: JP |
|
WWP | Wipo information: published in national office |
Ref document number: 10533320 Country of ref document: US |